Patients with high SCD risk: a life after cardioverter-defibrillators implantation (single-center observational trial)
Abstract
It’s known that implantable cardioverter-defibrillator (ICD) is an effective instrument of sudden cardiac death (SCD) decrease. Meanwhile CD implantation doesn’t always improve life prognosis. Cardiovascular mortality (CVM), a structure and incidence of rhythm disorders and ICD-related events in patients with a high SCD risk after CD implantation were studied during this observational retrospective single-center trial.
An estimated 5-year survival rate was 19.6%. High incidence of ventricular arrhythmias (51%) and atrial flutter/fibrillation (20%) was revealed. 2 patients underwent endocardial lead extraction. ICD therapy was used in 38.6% patients and in 37% of them it was inappropriate. Study results showed that left ventricular ejection fraction measured before CD is a valuable CVM predictor in this cohort of patients.
Keywords:implantable cardioverter- defibrillator, sudden cardiac death, heart failure
Clin Experiment Surg. Petrovsky J. 2018; 6 (3): 98–106.
doi: 10.24411/2308-1198-2018-13011. Received: 10.04.2018. Accepted: 10.08.2018.
References
1. Clinical recommendations for conducting electrophysi- ological studies, catheter ablation and the use of implantable antiarrhythmic devices. In: A.Sh. Revishvili (ed.). Moscow, 2017. (in Rus- sian)
2. Gordeeva M.V., Mitrofanova L.B., Pakhomov A.V., Velesvlavova O.E., et al. Sudden cardiac death in adolescents and young adults. Vestnik aritmologii [Bulletin of Arrhythmology]. 2012; (68): 34–44. (in Russian)
3. Ardashev A.V., Arutyunov G.P., Zhelyakov E.G., Belenkov Yu.N. The mechanisms and causes of sudden cardiac death. factors and risk stratification in clinical practice. definitions and terms. Klinicheskaya praktika [Clinical Practice]. 2014; (4): 3–12. (in Russian)
4. Khan S., Ghimire S., Talluri S., et al. Implantable cardioverter defibrillator in nonischemic cardiomyopathy: a systematic review and meta-analysis. J Arrhythm. 2017; 34 (1): 4–10.
5. Damrina E.V., Ilov N.N., Nechepurenko A.A. A value of peri- odic intracardiac electrograms used in the remote monitoring systems. Kreativnaya kardiologiya [Creative Cardiology]. 2016; 10 (3): 231–8. (in Russian)
6. Fischer A., Silver M., Sterns L., et al. Underutilization of remote monitoring systems after receiving an implantable cardioverter defibrillator shock: data from the shock-less trial. J Am Coll Cardiol. 2012; 59 (13).
7. Stoddard M.F., Labovitz A.J., Stevens L.L., et al. Effects of electrophysiologic studies resulting in electrical countershock or burst pacing on left ventricular systolic and diastolic function. Am Heart J. 1988; 116: 364–70.
8. Stockburger M., Krebs A., Nitardy A., et al. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death. Pacing Clin Electrophysiol. 2009; 32 (1): S16–20.
9. Looi K.L., Sidhu K., Cooper L., et al. Long-term outcomes of heart failure patients who received primary prevention implantable cardioverter-defibrillator: an observational study. J Arrhythm. 2017; 34 (1): 46–54.
10. Thune J.J., Pehrson S., Nielsen J.C., et al. Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). Am Heart J. 2016; 179: 136–41.
11. Ilov N.N., Nechepurenko A.A., Damrina E.V., Kulikova E.A., et al. Optimization of activities of Federal Center of Cardivascular Surgery using the system of remote monitoring in patients with implanted antiarrhythmic devices. Vestnik aritmologii [Bulletin of Arrhythmology]. 2014; (78): 53–7. (in Russian)
12. Masri A., Hammadah M., Adelstein E., et al. Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials. Cardiovasc Diagn Ther. 2017; 7 (4): 397–404.
13. 13. Zapara V.V., Vdovenko L.G., Kosykh L.N. Diagnosis of cardiac rhythm disturbances in patients with chronic heart failure with episodes of painless myocardial ischemia using the Holter ECG monitoring method. Vestnik aritmologii [Bulletin of Arrhythmology]. 2003; (32): 38. (in Russian)
14. Gurevich M.A. Heart rhythm disturbances and their correction in chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2005; (3): 5–10. (in Rus- sian)
15. Revishvili A.Sh., Neminushchy N.M. Current implantable cardioverter-defibrillator therapy: progress and standardization. Vestnik aritmologii [Bulletin of Arrhythmology]. 2017; (87): 33–41. (in Russian)
16. Tarakji K.G., Ellis C.R., Defaye P., et al. Cardiac implantable electronic device infection in patients at risk. Arrhythm Electrophysiol Rev. 2016; 5 (1): 65–71.
17. Greenspon A.J., Patel J.D., Lau E., et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011; 58: 1001–6.
18. Poole J.E., Gleva M.J., Mela T., et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010; 122: 1553–61.
19. Ganga H.V., Maan A., Kevin Heist E. Should primary prevention ICDs still be placed in patients with non-ischemic cardiomyopathy? A review of the evidence. Curr Cardiol Rep. 2018; 20 (5): 31.
20. Kleemann T., Strauss M., Kouraki K., et al. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients. Europace. 2015; 17 (7): 1068–75.
21. Kuhl E.A., Dixit N.K., Walker R.L., et al. Measurement of patient fears about implantable cardioverter defi brillator shock: an initial evaluation of the Florida Shock Anxiety Scale. Pacing Clin Electrophysiol. 2006; 29: 614–8.
22. Crossmann A., Pauli P., Dengler W., et al. Stability and cause of anxiety in patients with an implantable cardioverter-defibrillator: a longitudinal two-year follow-up. Heart Lung. 2007; 36: 87–95.
23. Sweeney M.O., Sherfesee L., DeGroot P.J. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010; 7: 353–60.
24. Bencardino G., Di Monaco A., Rio T., et al. The association between ICD interventions and mortality is independent of their modality: clinical implications. J Cardiovasc Electrophysiol. 2014; 25 (12): 1363–7.
25. Greenlee R.T., Go A.S., Peterso P.N., et al. Device therapies among patients receiving primary prevention implantable cardioverter-debrillators in the cardiovascular research network. J Am Heart Assoc. 2018; 7: e008292.
26. Sears S.F., Rosman L., Sasaki S., et al. Defibrillator shocks and their effect on objective and subjective patient outcomes: results of the PainFree SST clinical trial. Heart Rhythm. 2018; 15 (5): 734–40.
27. Wathen M.S., Sweeney M.O., DeGroot P.J., et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001; 104 (7): 796–801.
28. Grosse-Meininghaus D., Siebels J., Wolpert Ch., et al. Ef- ficacy of antitachycardia pacing confirmed by stored electrograms. A retrospective analysis of 613 stored electrograms in implantable defibrillators. Z Kardiol. 2002; 91 (5): 396–403.
29. Wathen M.S., DeGroot P.J., Sweeney M.O., et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004; 110 (17): 2591–6.
30. Hofer D., Steffel J., H rlimann D., et al. Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice-an underestimated complication? J Interv Card Electrophysiol. 2017; 50 (3): 219–26.
31. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008; 359 (10): 1009–17.
32. Wilkoff B.L., Fauchier L., Stiles M.K., et al. 2015 HRS/EHRA/ APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J Arrhythm. 2016; 32 (1): 1–28.